Market News How it works Learn FAQ
| RCT 0.084 10.38% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2377 7.31% | AZTR 1.51 111.19% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SOXL 90.5 8.31% | INTC 90.47 4.04% | SHFS 0.094 -29.00% | VALE 12 -3.23% | NVDA 216.019 2.40% | CLRO 4.97 52.92% | NOK 8.64 6.14% | TSLL 10.76 10.25% | JBLU 2.37 -9.71% | CRWV 55.19 1.76% | GCDT 0.1497 -14.99% | SOXS 47.98 -8.54% | ABEV 2.83 -14.24% | NWGL 0.0857 4.51% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | RIG 6.53 1.87% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | SID 0.9118 -22.73% | RBNE 0.1671 -12.05% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | PLUG 1.37 -0.72%
MNMonopar Therapeutics Inc. logo

Monopar Therapeutics Inc. (MNPR)

NASDAQ · Currency in USD
$70.54 ▼ -0.11 (-0.16%)
At close: Oct 26, 4:00 PM ET. Market closed.
$70.54 ▲ +0.00 (+0.00%)
After hours: Oct 26, 4:10 PM ET

Summary

Previous Close
$70.65
Open
$71.55
Day's Range
$69.42 – $72.79
52 Week Range
$50.07 – $124.82
Volume
79,014
Avg. Volume
200,563
Market Cap
$473.48M
Beta (5Y Monthly)
1.51
PE Ratio (TTM)
--
EPS (TTM)
-$2.09
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$126.00

Profile: Monopar Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
22
CEO
Chandler D. Robinson

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.86
DateEst.Actual
Aug 12, 2026-$0.64-$0.62Beat
May 14, 2026-$1.06-$0.46Beat
Mar 27, 2026-$0.51-$0.61Miss
Nov 13, 2025-$0.46-$0.48Miss
Aug 12, 2025-$0.47-$0.35Beat
May 13, 2025-$0.65-$0.38Beat

Analyst view

Consensus price target
$126.00 ▲ +78.6%
Range $105.00 – $145.00
Rating: Buy
Buy 79% · Hold 21% · Sell 0%

Get free alerts on MNPR and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.